Halozyme Therapeutics, Inc. reiterating its financial guidance for 2022, which was last provided on August 9, 2022 as a result of the close of the Antares Pharma transaction and strong year-to-date results. For the full year 2022, the Company expects: total revenue of $655 million to $685 million, representing growth of 48% to 55% over 2021 total revenue primarily driven by projected revenue contribution from the Antares business of $115 million to $125 million; GAAP operating income of $240 million to $265 million, which includes one-time transaction costs of approximately $45 million and amortization of approximately $80 million related to the Antares acquisition; GAAP net income of $170 million to $195 million; GAAP diluted earnings per share of $1.20 to $1.35 due to acquisition related costs in 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
49.5 USD | -0.24% | -2.65% | +33.93% |
Jun. 13 | Halozyme Therapeutics Insider Sold Shares Worth $1,006,300, According to a Recent SEC Filing | MT |
Jun. 11 | Halozyme Therapeutics May Seeks M&A | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+33.93% | 6.3B | |
+18.15% | 124B | |
+18.02% | 112B | |
+5.07% | 22.94B | |
-12.75% | 22.22B | |
-9.86% | 17.02B | |
-14.97% | 16.88B | |
-39.94% | 16.87B | |
+2.80% | 13.63B | |
+27.39% | 11.61B |
- Stock Market
- Equities
- HALO Stock
- News Halozyme Therapeutics, Inc.
- Halozyme Therapeutics, Inc. Reiterates Financial Guidance for the Year 2022